Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903

This article was originally published here

Theravance is considering that the TD-0903 can block the cytokine storm linked with ALI and prevent progression to acute respiratory distress syndrome (ARDS). According to the company, the

The post Theravance Biopharma doses first patient in phase 2 Covid-19 trial with JAKi inhibitor TD-0903 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply